Physician profile
Robert Mignacca
NPI 1891707733
$1,916.60
in general payments reported to CMS, 2019-2025
11 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $248 · 2021: $660 · 2022: $253 · 2024: $18.43 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $175 · Food and Beverage: $58.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $175.00 |
| Food and Beverage | $58.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $1,082.94 | 2019-2025 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $192.60 | 2020-2022 | |
| Shire North American Group INC | $159.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $147.75 | 2019-2022 | |
| Genzyme Corporation | $91.06 | 2022 | |
| Grifols USA, LLC | $60.89 | 2019-2020 | |
| Genentech, INC. | $49.95 | 2021 | |
| Genentech USA, INC. | $48.05 | 2019 | |
| Amgen INC. | $37.49 | 2019 | |
| Pfizer INC. | $29.76 | 2021-2024 | |
| Global Blood Therapeutics, INC. | $16.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mignacca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.